Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AB Science

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

Innovate UK awards Sano Genetics £330,000 grant for ALS study

The project will chart the psychological impacts of having a genetic predisposition to ALS

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

- PMLiVE

UK Government commit £50m to motor neurone disease research

The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

- PMLiVE

Verge Genomics begins human trials with AI-sourced ALS drug

VRG50635 was discovered by the company’s all-in-human, AI-powered platform

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG received a £2.68m Innovative UK award to help fund research into treatments for Parkinson’s disease, motor neurone disease and other neurodegenerative diseases

- PMLiVE

Six UK universities receive grant for research into motor neurone disease

The grant was given by the Medical Research Council and the National Institute for Health and Care Research, along with charities LifeArc, MND Association, My Name’5 Doddie Foundation and MND...

- PMLiVE

NRG Therapeutics receives £2.68m Innovate UK Award

The funds will be used for research into new treatments for Parkinson’s and motor neurone disease

Biogen Idec building

Biogen’s ALS drug tofersen misses phase 3 endpoint

Following these results, Biogen will now expand its early access programme for tofersen to enable all eligible SOD1-ALS patients worldwide to receive the drug free of charge

Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma

Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links